Company intelligence / Profile preview
Neutec Pharmaceuticals
Istanbul, Turkeyneutec.eu ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Mycograb received orphan drug status in EU and US; both Mycograb and Aurograb were late-stage assets at time of Novartis acquisition.[1][6] The Turkish entity has a large portfolio of branded generics and respiratory products but does not publicly disclose clinical trial results.
- Therapeutic areas
- PulmonologyOncologyInfectious DiseasesGastroenterologyWomen's Health
- Modalities
- Small moleculesInhaled therapeutics/dry powder inhalersBranded generics and value-added genericsRecombinant antibodies ("grabs")
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Takeda Pharmaceutical Company Limited
Beyond the preview
Go deeper on Neutec Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neutec Pharmaceuticals.